

1 **Impaired performance of SARS-CoV-2 antigen-detecting rapid tests at elevated**
2 **temperatures**

3 Verena Haage¹, Edmilson Ferreira de Oliveira-Filho¹, Andres Moreira-Soto¹, Arne
4 Kühne¹, Carlo Fischer¹, Jilian Sacks³, Victor Max Corman^{1,2}, Marcel A. Müller^{1,2},
5 Christian Drosten^{1,2}, Jan Felix Drexler^{1,2*}

6 ¹Institute of Virology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie
7 Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin,
8 Germany

9 ²German Centre for Infection Research (DZIF), Associated Partner Charité-
10 Universitätsmedizin Berlin, Berlin, Germany

11
12 *Correspondence: Jan Felix Drexler, Helmut-Ruska-Haus, Institute of Virology, Campus
13 Charité Mitte, Charitéplatz 1, 10098 Berlin, Germany; Email: felix.drexler@charite.de

14
15
16 **Key words:** SARS-CoV-2, rapid antigen test, temperature stability, tropics, diagnostics

17

18

19

20

21

22 **Abstract**

23 Rapid antigen-detecting tests (Ag-RDTs) can complement molecular diagnostics for
24 COVID-19. The recommended temperature for storage of SARS-CoV-2 Ag-RDTs ranges
25 between 5-30°C. In many countries that would benefit from SARS-CoV-2 Ag-RDTs, mean
26 temperatures exceed 30°C. We assessed analytical sensitivity and specificity of eleven
27 commercially available SARS-CoV-2 Ag-RDTs using different storage and operational
28 temperatures, including (i) long-term storage and testing at recommended conditions, (ii)
29 recommended storage conditions followed by 10 minutes exposure to 37°C and testing at
30 37°C and (iii) 3 weeks storage followed by testing at 37°C. The limits of detection of SARS-
31 CoV-2 Ag-RDTs under recommended conditions ranged from 8.2×10^5 - 7.9×10^7 genome
32 copies/ml of infectious SARS-CoV-2 cell culture supernatant. Despite long-term storage
33 at recommended conditions, 10 minutes pre-incubation of Ag-RDTs and testing at 37°C
34 resulted in about ten-fold reduced sensitivity for 46% of SARS-CoV-2 Ag-RDTs, including
35 both Ag-RDTs currently listed for emergency use by the World Health Organization. After
36 3 weeks of storage at 37°C, 73% of SARS-CoV-2 Ag-RDTs exhibited about ten-fold
37 reduced sensitivity. Specificity of SARS-CoV-2 Ag-RDTs using cell culture-derived human
38 coronaviruses HCoV-229E and HCoV-OC43 was not affected by storage and testing at
39 37°C. In summary, short- and long-term exposure to elevated temperatures likely impairs
40 sensitivity of several SARS-CoV-2 Ag-RDTs that may translate to false-negative test
41 results at clinically relevant virus concentrations compatible with inter-individual
42 transmission. Ensuring appropriate transport and storage conditions, and development of
43 tests that are more robust across temperature fluctuations will be important for accurate
44 use of SARS-CoV-2 Ag-RDTs in tropical settings.

45 **Introduction**

46 Advantages of SARS-CoV-2 antigen-detecting rapid diagnostic tests (Ag-RDTs) include
47 fast results and their applicability on site without dependence on laboratory settings. Ag-
48 RDTs are not intended to replace real-time RT-PCR as the gold standard for SARS-CoV-
49 2 diagnostics (1, 2), but can be deployed for surveillance in high-risk environments or
50 areas with insufficient laboratory capacity. With a constantly growing number of
51 commercially available Ag-RDTs on the global market, the number of studies validating
52 Ag-RDTs from different manufacturers is increasing rapidly (3-9). Those validation studies
53 have so far not focused on the performance of Ag-RDTs under conditions that differ from
54 recommended storage and test execution conditions (5-30°C), such as those observed in
55 tropical settings where ambient temperatures commonly exceed 30°C (**Figure 1A**). This
56 is challenging because tropical regions are strongly affected by the SARS-CoV-2
57 pandemic as evident from total cases reported from India, Brazil, Argentina, and
58 Colombia, four out of the ten most affected countries worldwide by November 2020
59 (**Figure 1B**).

60 Several studies have shown the need for validation of diagnostic tools in resource-limited
61 tropical regions because co-endemic diseases can affect diagnostic test performance (10-
62 14). The same might also apply to the environmental conditions under which Ag-RDTs
63 are transported, stored and used. Temperature tolerance of SARS-CoV-2 diagnostic tools
64 or environmental stability requirements have been previously discussed as hurdles and
65 corresponding guidelines for stability testing of *in vitro* diagnostics are provided by the
66 World Health Organization (WHO) (15, 16). To date, knowledge about temperature
67 stability of SARS-CoV-2 Ag-RDTs is scarce.

68 To validate the performance of SARS-CoV-2 Ag-RDT in tropical settings, we compared
69 analytical sensitivity and specificity of eleven SARS-CoV-2 Ag-RDTs using recommended
70 and elevated temperatures.

71

72 **Materials and Methods**

73 **Storage and testing of SARS-CoV-2 Ag-RDTs at 37°C**

74 For storage at recommended conditions, the tests were stored at ambient temperature
75 and were monitored that the room temperature stayed between 15-25°C. For storage at
76 37°C, SARS-CoV-2 Ag-RDTs were removed from cartons for space reasons and stored
77 in plastic bags in a 37°C incubator for 19-21 days for sensitivity and 8-9 days for specificity
78 testing. All tests were kept in their individual foil packaging until use. For experiments with
79 infectious SARS-CoV-2, Ag-RDTs were transferred to a BSL-3 laboratory and stored in a
80 37°C incubator until test application. For specificity testing with infectious human
81 coronavirus (HCoV)-229E and HCoV-OC43, SARS-CoV-2 Ag-RDTs were transferred to
82 a BSL-2 laboratory and stored in a 37°C incubator until test validation. For experiments
83 testing short-term exposure to 37°C following storage at recommended temperatures,
84 SARS-CoV-2 Ag-RDTs were transferred to a BSL-3 laboratory and stored for 10 minutes
85 in a 37°C incubator until test operation. After application of SARS-CoV-2, HCoV-229E or
86 HCoV-OC43 cell culture supernatant in a biological safety cabinet, Ag-RDTs were further
87 incubated in a 37°C incubator until readout of the results.

88

89

90 **Analytical sensitivity**

91 SARS-CoV-2 (BetaCoV/Munich/ChVir984/2020) was grown on Vero E6 cells (C1008;
92 African green monkey kidney cells) and maintained in DMEM containing 10% FCS at
93 37°C with 5% CO₂. Viral RNA was extracted from cell culture supernatant using the
94 QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's
95 instructions. RNA concentration was determined by specific real-time RT-PCR and *in*
96 *vitro*-transcribed RNA standards designed for absolute quantification of virus
97 concentrations (17, 18).

98 For determination of the limit of detection (LOD), a SARS-CoV-2 stock (3.1×10^9 copies/ml)
99 was serially diluted in plain DMEM and 5µl/dilution were added to the extraction buffer of
100 the respective kit for validation experiments. For the Coris COVID-19 Ag Respi-Strip test,
101 5µl of SARS-CoV-2 supernatant was added to 95µl of PBS to reach the required sample
102 volume of 100µl prior to addition of LY-S buffer to the sample for test validation. Initially,
103 validation experiments were performed in triplicates for a small subset of tests
104 (ActivXpress, Genedia, ichroma, JOYSBIO) at recommended conditions (i) with all three
105 replicates showing the same result (**Supplementary Table 1**). Consequently, validation
106 experiments for all included tests were subsequently performed in duplicates due to a
107 limited amount of available tests for all conditions tested. LOD was defined as the lowest
108 dilution at which both replicates were positive. A dilution factor correction was applied
109 based on the volume of extraction buffer (range between kits, 100-500µl) provided by
110 each SARS-CoV-2 Ag-RDT kit.

111

112

113 **Analytical specificity**

114 Specificity was tested using cell culture supernatant of HCoV-229E and HCoV-OC43,
115 grown on CaCo-2 cells. Quantification of viral stocks was performed by RT-PCR using an
116 in house protocol and photometrically quantified *in vitro*-transcribed RNA standards as
117 described above. 5µl of stocks were directly used for validation experiments. The required
118 sample volume of 100µl for the Coris COVID-19 Ag Respi-Strip was reached as described
119 above. Experiments were performed in duplicates.

120

121 **Interpretation of test results**

122 Tests were performed according to the test-specific supplier instructions for use, except
123 for the sample preparation as noted above. Results in the form of a band on
124 immunochromatography paper were scored independently by two persons except for the
125 reader-based tests Bioeasy 2019-nCoV Ag and ichroma - COVID-19 Ag. In case of
126 discrepancy for visual tests, a third person was consulted to reach a final decision. Results
127 were defined as unclear when a weak, discontinuous band or smear was observed that
128 could not be clearly defined as a positive or negative result. In case of test failure indicated
129 by absence of a visible positive control band, the test procedure was repeated with the
130 same sample.

131

132 **World heat map**

133 Data of maximum temperatures of the hottest month (°C) on country level at the spatial
134 resolution of 2.5 min were obtained from WorldClim 2 (19). National means were

135 calculated using the exactextractr package in R version 4.0.2. Data on COVID-19 cases
136 were obtained from Worldmeter (20) and visualized using the GraphPad Prism software.

137

138 **Results**

139 At present, there are at least 119 SARS-CoV-2 Ag-RDTs commercially available (21).
140 Eleven of those SARS-CoV-2 rapid antigen tests were selected for temperature stability
141 validation based on the availability of clinical performance data (3), and manufacturing by
142 leading suppliers implying availability on the global market (**Table 1**). Subsequently,
143 analytical performance of selected SARS-CoV-2 Ag-RDTs was assessed following
144 storage and application of tests under recommended conditions as well as elevated
145 temperatures (termed tropical conditions henceforth), using three different experimental
146 settings.

147

148 **Table 1. Overview of SARS-CoV-2 rapid antigen tests included in the study**

ID	Test	Manufacturer	Readout	Lot No.
I	Panbio™ COVID-19 Ag Rapid Test	Abbott Laboratories	Visual	41ADF012A
II	ActivXpress + COVID-19 Antigen Complete Testing Kit	Edinburgh Genetics	Visual	AG20200905
III	Bioeasy 2019-nCoV Ag Fluorescence Rapid Test Kit	Shenzhen Bioeasy Biotechnology Co., Ltd	Reader	2003N406
IV	Clinitest Rapid COVID-19 Antigen Test	Siemens Healthineers	Visual	2010184

V	Covid.19 Ag Respi-Strip	Coris BioConcept	Visual	43871J2008 43760I2015
VI	COVID-19 Ag	Genedia	Visual	643X2005
VII	ichroma - COVID-19 Ag	Boditech Med	Reader	SRQHA27
VIII	COVID-19 Antigen Rapid Test Kit	JOYSBIO (Tianjin) Biotechnology Co., Ltd.	Visual	2020092409
IX	NowCheck COVID-19 Ag test	BIONOTE INC.	Visual	1901D002 Code GEN
X	SARS-CoV-2 Rapid Antigen Test	Roche Diagnostics	Visual	QCO3020083 QCO390003I/Sub:I-2 QCO390011A/Sub:A-2
XI	STANDARD Q COVID-19 Test	SD Biosensor, Inc.	Visual	QCO3020040A

149
150
151 The first setting was (i) storage at recommended conditions (room temperature (rt); 15-
152 30°C) for 1-6 months and test incubation at recommended conditions (rt; 15-30°C). The
153 second setting was (ii) storage at recommended conditions (rt; 15-30°C) for 1-6 months,
154 10 minutes pre-incubation of tests at 37°C prior to testing and test incubation at 37°C so
155 as to mimic recommended storage of kits prior to test usage under non air-conditioned
156 conditions in tropical settings. The third setting was (iii) storage under tropical conditions
157 (37°C) for 19-21 days followed by test incubation at 37°C to mimic non air-conditioned
158 storage and test application in tropical settings (**Figure 2**).

159 First, we determined analytical sensitivity at recommended conditions by determining the
160 limit of detection (LOD) of SARS-CoV-2 Ag-RDTs at room temperature using serial

161 dilutions of SARS-CoV-2 cell culture supernatant (dilution range: 7.2×10^6 copies/ml to
162 3.1×10^9 copies/ml; **Table 2**) following storage for 1-6 months at room temperature. Prior
163 to performing all experiments in duplicates we validated analytical sensitivity for a small
164 subset of tests at recommended conditions in triplicates, showing that results for
165 duplicates and triplicates were identical (**Supplementary Table 1**). As extraction buffer
166 volumes differ between manufacturers and a constant volume of SARS-CoV-2
167 supernatant was applied for validation experiments, the limit of detection (LOD) for each
168 Ag-RDT was calculated by correcting for the respective dilution factor. The dilution-factor
169 corrected limit of detection (LOD) for validated SARS-CoV-2 Ag-RDTs ranged from
170 8.2×10^5 copies/ml to 7.9×10^7 copies/ml of SARS-CoV-2 cell culture supernatant (**Table 2**).
171 Those LODs were consistent with previously published virus concentrations for validation
172 of Ag-RDTs using clinical samples (3), suggesting robustness of our data. Our data also
173 highlight profound differences in analytical sensitivity of up to 100-fold for SARS-CoV-2
174 Ag-RDTs from different manufacturers.

175

176

177

178

179

180

181

182 **Table 2. Analytical Sensitivity of SARS-CoV-2 rapid antigen tests at recommended**
 183 **storage and test conditions**

SARS-CoV-2 (copies/ml)	I	II	III	IV	V	VI	VII	VIII	IX	X	XI
3.1x10 ⁹	++	++	++	++	++	++	++	++	++	++	++
7.0x10 ⁸	++	++	++	++	?	?	++	++	++	++	++
7.0x10 ⁷	++	++	-	+	-	-	++	+	++	+	++
7.2x10 ⁶	-	-	-	-	-	-	-	-	-	-	-
Corrected SARS-CoV-2 LOD (copies/ml)	1.2x10 ⁶	1.4x10 ⁶	7.0x10 ⁶	1.1x10 ⁶	7.9x10 ⁷	4.6x10 ⁷	8.2x10 ⁵	1.4x10 ⁶	1.0x10 ⁶	1.0x10 ⁶	1.0x10 ⁶

184 I: Abbott; II ActivXpress; III Bioeasy; IV Clinitest; V Coris; VI Genedia; VII ichroma; VIII
 185 JOYSBIO; IX NowCheck; X Roche; XI Standard Q. ++ positive; + weak positive; -
 186 negative; ? unclear result. LOD: limit of detection.

187
 188 We then assessed analytical sensitivity of SARS-CoV-2 Ag-RDTs following short- and
 189 long-term exposure to 37°C (settings (ii) and (iii); **Figure 2**) by determining the level of
 190 detection (LOD) using identical serial dilutions of SARS-CoV-2 cell culture supernatant.
 191 The analytical sensitivity of about half of the evaluated SARS-CoV-2 Ag-RDTs (five out of
 192 eleven; 46%) was already compromised by about ten-fold when tests were stored under
 193 recommended conditions but exposed to 37°C for only ten minutes prior to testing at 37°C
 194 (**Figure 3**). After 19-21 days storage at 37°C and testing at 37°C, eight out of the eleven
 195 SARS-CoV-2 Ag-RDTs (73%) showed an about ten-fold reduction in analytical sensitivity
 196 when compared to recommended temperatures.

197 Additionally, analytical specificity of SARS-CoV-2 Ag-RDTs under recommended and
198 under tropical storage and test application conditions ((i) and (iii); **Figure 2**) was examined
199 by testing for cross-reactivity with the ubiquitous HCoV-229E (2.9×10^7 copies/ml) and
200 HCoV-OC43 (1.0×10^6 copies/ml) (22, 23). Those HCoV concentrations were selected
201 according to the guidelines on analytical specificity testing for SARS-CoV-2 Ag-RDTs
202 published by the German Federal institute for vaccines and biomedicines (24). SARS-
203 CoV-2 Ag-RDTs showed no cross-reactivity with HCoV-229E or HCoV-OC43 upon
204 storage and testing at elevated temperatures (**Table 3**).

205
206 **Table 3. Analytical Specificity of SARS-CoV-2 rapid antigen tests at recommended**
207 **and tropical storage and test application conditions**

Condition	Virus	Cps/ml	I	II	III	IV	V	VI	VII	VIII	IX	X	XI
(i)	HCoV-229E	2.9×10^7	-	-	-	-	-	-	-	-	-	-	-
(iii)			-	-	-	-	-	-	-	-	-	-	-
(i)	HCoV-OC43	1.0×10^6	-	-	-	-	-	-	-	-	-	-	-
(iii)			-	-	-	-	-	-	-	-	-	-	-

208 I: Abbott; II ActivXpress; III Bioeasy; IV Clinitest; V Coris; VI Genedia; VII ichroma; VIII
209 JOYSBIO; IX NowCheck; X Roche; XI Standard Q.+ positive; - negative. Cps, Genome
210 copies.

211

212

213

214

215 Discussion

216 Our study highlights that even short-term exposure to elevated temperatures may
217 compromise sensitivity of currently available SARS-CoV-2 Ag-RDTs.

218 Our data are consistent with impaired sensitivity of other Ag-RDTs at elevated
219 temperatures, including Malaria rapid diagnostic tests (MRDTs). An assessment of five
220 MRDTs reported a 13% to 53% decline in sensitivity for three MRDTs following 90 days
221 of storage at 35°C (25). Moreover, an evaluation assessing temperature stability of
222 dengue NS1 antigen-based RDTs at 35°C showed a gradual decline in test sensitivity for
223 seven out of eight tested dengue Ag-RDTs after storage for about 20 days at elevated
224 temperatures (26). Beyond storage, elevated temperatures during shipment can also
225 affect Ag-RDT performance. Supply chains of MRDTs were studied in Burkina Faso,
226 Senegal, Ethiopia, the Philippines and Cambodia, demonstrating regular exceeding of
227 30°C during transport (27, 28). Consequently, the WHO recommends heat stability testing
228 between 35°C and 40°C for MRDTs (29) and supply and delivery chains to tropical
229 countries must contain adequate cold chains (30).

230 As discussed by others, temperature stability guidelines for *in vitro* diagnostics exist,
231 however there are currently no specific guidelines for the validation of Ag-RDTs regarding
232 temperature stability (31-34). Common validation guidelines including environmental
233 conditions could be a first step towards globally reliable diagnostics.

234 At the same time, our data imply a huge challenge to tropical countries with regard to
235 adequate storage of SARS-CoV-2 Ag-RDTs. Besides storage capacity, temperature
236 control and monitoring of storage facilities is required, especially for long-term storage of
237 Ag-RDTs. To guarantee temperature-regulated storage, a certain level of infrastructure is

238 required, ideally air-conditioned facilities with temperature monitors and secured power
239 supply. However, these requirements are not realistic and appropriate concepts for
240 adequate storage in remote areas without electricity and rudimentary infrastructure will be
241 required.

242 Our study is limited by focusing on analytical test performance exclusively for reasons of
243 comparability of test results across the different conditions and based on limited access
244 to clinical samples. An additional limitation of our study is the use of duplicates for some
245 tests instead of a higher number of replicates, which was due to the limited availability of
246 all tests included in the study. Further studies will be required to assess test performance
247 upon tropical storage and application in tropical conditions using large numbers of clinical
248 samples. Additionally, not only the effect of elevated temperature but also the effect of
249 increased humidity on test performance will have to be assessed. Finally, future studies
250 documenting the impact of decreased temperature on test performance may also be
251 needed. Despite these limitations, our study presents a robust resource for further
252 validation studies as a high number of SARS-CoV-2 Ag-RDTs was included. Additionally,
253 our data on an overall impaired performance of Ag-RDTs at elevated temperatures are
254 consistent across tests and analytical sensitivity for several tests was identical upon usage
255 of either duplicates or higher numbers of replicates.

256 In sum, it was shown previously that clinically relevant virus concentrations of about 10^6
257 genome copies per ml suffice for virus isolation and culture and therefore serve as a
258 correlate for infectivity (35, 36). Our study strongly suggests that short- and long-term
259 exposure to elevated temperatures may compromise sensitivity of SARS-CoV-2 Ag-RDTs

260 to an extent that may lead to false-negative test results at clinically relevant virus
261 concentrations, potentially enhancing SARS-CoV-2 spread in tropical settings.

262

263 **Funding**

264 This study is based on research funded in part by the Bill & Melinda Gates Foundation
265 (grant ID INV-005971). The findings and conclusions contained within are those of the
266 authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates
267 Foundation. The study was further supported in part by the Foundation for Innovative New
268 Diagnostics (FIND), including procurement of some test kits.

269

270 **Conflicts of Interest:** The authors declare no conflict of interest.

271

272 **Author Contributions:** V.H.: conceptualization, investigation, validation, formal analysis,
273 data curation, writing – original draft preparation, visualization. E.F.: methodology,
274 investigation, validation. A.M.S.: investigation, validation, visualization. A.K.: investigation.
275 C.F.: visualization, software. J.S.: methodology, resources, writing. V.M.C.: methodology.
276 C.D.: methodology. J.F.D.: conceptualization, methodology, resources, writing – original
277 draft preparation, visualization, supervision, project administration, funding acquisition. All
278 authors have read and agreed to the published version of the manuscript.

279

280

281

282

283 References

- 284 1. Jayamohan H, Lambert CJ, Sant HJ, Jafek A, Patel D, Feng H, Beeman M, Mahmood T,
285 Nze U, Gale BK. 2020. SARS-CoV-2 pandemic: a review of molecular diagnostic tools
286 including sample collection and commercial response with associated advantages and
287 limitations. *Analytical and Bioanalytical Chemistry* doi:10.1007/s00216-020-02958-1.
- 288 2. European Centre for Disease Prevention and Control S. 2020. Options for the use of
289 rapid antigen tests for COVID-19 in the EU/EEA and the UK. Technical Report.
- 290 3. Corman VM, Haage VC, Bleicker T, Schmidt ML, Mühlemann B, Zuchowski M, Jó Lei
291 WK, Tscheak P, Möncke-Buchner E, Müller MA, Krumbholz A, Drexler JF, Drosten C.
292 2020. Comparison of seven commercial SARS-CoV-2 rapid Point-of-Care Antigen tests.
293 medRxiv doi:10.1101/2020.11.12.20230292:2020.11.12.20230292.
- 294 4. Iglói Z, Velzing J, van Beek J, van de Vijver D, Aron G, Ensing R, Benschop K, Han W,
295 Boelsums T, Koopmans M, Geurtsvankessel C, Molenkamp R. 2020. Clinical evaluation
296 of the Roche/SD Biosensor rapid antigen test with symptomatic, non-hospitalized
297 patients in a municipal health service drive-through testing site. medRxiv
298 doi:10.1101/2020.11.18.20234104:2020.11.18.20234104.
- 299 5. Krüger LJ, Gaeddert M, Köppel L, Brümmer LE, Gottschalk C, Miranda IB, Schnitzler P,
300 Kräusslich HG, Lindner AK, Nikolai O, Mockenhaupt FP, Seybold J, Corman VM,
301 Drosten C, Pollock NR, Cubas-Atienzar AI, Kontogianni K, Collins A, Wright AH, Knorr B,
302 Welker A, de Vos M, Sacks JA, Adams ER, Denkinger CM. 2020. Evaluation of the
303 accuracy, ease of use and limit of detection of novel, rapid, antigen-detecting point-of-
304 care diagnostics for SARS-CoV-2. medRxiv
305 doi:10.1101/2020.10.01.20203836:2020.10.01.20203836.
- 306 6. Lindner AK, Nikolai O, Rohardt C, Burock S, Hülso C, Bölke A, Gertler M, Krüger LJ,
307 Gaeddert M, Tobian F, Lainati F, Seybold J, Jones TC, Hofmann J, Sacks JA,
308 Mockenhaupt FP, Denkinger CM. 2020. Head-to-head comparison of SARS-CoV-2
309 antigen-detecting rapid test with professional-collected anterior nasal versus
310 nasopharyngeal swab. medRxiv
311 doi:10.1101/2020.12.03.20243725:2020.12.03.20243725.
- 312 7. Lambert-Niclot S, Cuffel A, Le Pape S, Vauloup-Fellous C, Morand-Joubert L, Roque-
313 Afonso AM, Le Goff J, Delaugerre C. 2020. Evaluation of a Rapid Diagnostic Assay for
314 Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs. *J Clin Microbiol* 58.
- 315 8. Mertens P, De Vos N, Martiny D, Jassoy C, Mirazimi A, Cuypers L, Van den Wijngaert S,
316 Monteil V, Melin P, Stoffels K, Yin N, Mileto D, Delaunoy S, Magein H, Lagrou K, Bouzet
317 J, Serrano G, Wautier M, Leclipteux T, Van Ranst M, Vandenberg O, L-US-C-WDG,
318 Gulbis B, Brancart F, Bry F, Cantinieaux B, Corazza F, Cotton F, Dresselhuis M,
319 Mahadeb B, Roels O, Vanderlinden J. 2020. Development and Potential Usefulness of
320 the COVID-19 Ag Respi-Strip Diagnostic Assay in a Pandemic Context. *Frontiers in*
321 *Medicine* 7.
- 322 9. Mak GC, Cheng PK, Lau SS, Wong KK, Lau CS, Lam ET, Chan RC, Tsang DN. 2020.
323 Evaluation of rapid antigen test for detection of SARS-CoV-2 virus. *J Clin Virol*
324 129:104500.
- 325 10. Yadouleton A, Sander AL, Moreira-Soto A, Tchibozo C, Hounkanrin G, Badou Y, Fischer
326 C, Krause N, Akogbeto P, de Oliveira Filho EF, Dossou A, Brünink S, Aïssi MAJ,
327 Djingarey MH, Hounkpatin B, Nagel M, Drexler JF. 2021. Limited Specificity of Serologic
328 Tests for SARS-CoV-2 Antibody Detection, Benin. *Emerg Infect Dis* 27.
- 329 11. Nath H, Mallick A, Roy S, Sukla S, Basu K, De A, Biswas S. 2020. Dengue antibodies
330 can cross-react with SARS-CoV-2 and vice versa-Antibody detection kits can give false-
331 positive results for both viruses in regions where both COVID-19 and Dengue co-exist.
332 medRxiv doi:10.1101/2020.07.03.20145797:2020.07.03.20145797.

- 333 12. Lustig Y, Keler S, Kolodny R, Ben-Tal N, Atias-Varon D, Shlush E, Gerlic M, Munitz A,
334 Doolman R, Asraf K, Shlush LI, Vivante A. 2020. Potential antigenic cross-reactivity
335 between SARS-CoV-2 and Dengue viruses. *Clinical infectious diseases : an official*
336 *publication of the Infectious Diseases Society of America* doi:10.1093/cid/ciaa1207.
- 337 13. Ombelet S, Ronat JB, Walsh T, Yansouni CP, Cox J, Vlieghe E, Martiny D, Semret M,
338 Vandenberg O, Jacobs J. 2018. *Clinical bacteriology in low-resource settings: today's*
339 *solutions. Lancet Infect Dis* 18:e248-e258.
- 340 14. Fischer C, Drosten C, Drexler JF. 2019. The difficulties in obtaining reliable Zika virus
341 diagnostics. *Lancet Infect Dis* 19:240-241.
- 342 15. Vandenberg O, Martiny D, Rochas O, van Belkum A, Kozlakidis Z. 2020. Considerations
343 for diagnostic COVID-19 tests. *Nature Reviews Microbiology* doi:10.1038/s41579-020-
344 00461-z.
- 345 16. Organization WH. 2017. Technical guidance series (TGS) for WHO prequalification –
346 diagnostic assessment panels for quality assurance and quality control of in vitro
347 diagnostic medical devices. *Technical Guidance* vol. 6.
- 348 17. Drexler JF, Kupfer B, Petersen N, Grotto RM, Rodrigues SM, Grywna K, Panning M,
349 Annan A, Silva GF, Douglas J, Koay ES, Smuts H, Netto EM, Simmonds P, Pardini MI,
350 Roth WK, Drosten C. 2009. A novel diagnostic target in the hepatitis C virus genome.
351 *PLoS Med* 6:e31.
- 352 18. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink S,
353 Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S,
354 Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken
355 C, Koopmans MP, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV)
356 by real-time RT-PCR. *Euro Surveill* 25.
- 357 19. <http://www.worldclim.com/version2>. Accessed 25.11.2020.
- 358 20. <https://www.worldometers.info/coronavirus/#countries>. Accessed 25.11.2020.
- 359 21. <https://www.finddx.org/covid-19/pipeline>. Accessed 23.12.2020.
- 360 22. Annan A, Ebach F, Corman VM, Krumkamp R, Adu-Sarkodie Y, Eis-Hübinger AM,
361 Kruppa T, Simon A, May J, Evans J, Panning M, Drosten C, Drexler JF. 2016. Similar
362 virus spectra and seasonality in paediatric patients with acute respiratory disease, Ghana
363 and Germany. *Clin Microbiol Infect* 22:340-346.
- 364 23. Góes LGB, Zerbinati RM, Tateno AF, de Souza AV, Ebach F, Corman VM, Moreira-Filho
365 CA, Durigon EL, da Silva Filho L, Drexler JF. 2020. Typical epidemiology of respiratory
366 virus infections in a Brazilian slum. *J Med Virol* 92:1316-1321.
- 367 24. Arzneimittel Bflub. 2020. Mindestkriterien für SARS-CoV-2 Antigentests im Sinne
368 von § 1 Abs. 1 Satz 1 TestVO: Antigenschnelltests.
- 369 25. Chiodini PL, Bowers K, Jorgensen P, Barnwell JW, Grady KK, Luchavez J, Moody AH,
370 Cenizal A, Bell D. 2007. The heat stability of Plasmodium lactate dehydrogenase-based
371 and histidine-rich protein 2-based malaria rapid diagnostic tests. *Trans R Soc Trop Med*
372 *Hyg* 101:331-7.
- 373 26. Blacksell SD, Newton PN, Bell D, Kelley J, Mammen MP, Jr., Vaughn DW, Wuthiekanun
374 V, Sungkakum A, Nisalak A, Day NPJ. 2006. The Comparative Accuracy of 8
375 Commercial Rapid Immunochromatographic Assays for the Diagnosis of Acute Dengue
376 Virus Infection. *Clinical Infectious Diseases* 42:1127-1134.
- 377 27. Albertini A, Lee E, Coulibaly SO, Sleshi M, Faye B, Mationg ML, Ouedraogo K, Tsadik
378 AG, Feleke SM, Diallo I, Gaye O, Luchavez J, Bennett J, Bell D. 2012. Malaria rapid
379 diagnostic test transport and storage conditions in Burkina Faso, Senegal, Ethiopia and
380 the Philippines. *Malar J* 11:406.
- 381 28. Jorgensen P, Chanthap L, Rebuena A, Tsuyuoka R, Bell D. 2006. Malaria rapid
382 diagnostic tests in tropical climates: the need for a cool chain. *Am J Trop Med Hyg*
383 74:750-4.

- 384 29. World Health Organization FfIND, Center for Disease Control and Prevention. 2014.
385 Malaria rapid diagnostic test performance. Results of WHO product testing of malaria
386 RDTs, Round 5 2014.
- 387 30. Organization WH. 2004. The Use of Malaria Rapid Diagnostic Tests. Manila: World
388 Health Organization.
- 389 31. Phommasone K, Sengvilaipaseuth O, de Lamballerie X, Vongsouvath M, Phonemixay O,
390 Blacksell SD, Newton PN, Dubot-Pérès A. 2015. Temperature and the field stability of a
391 dengue rapid diagnostic test in the tropics. *Am J Trop Med Hyg* 93:33-39.
- 392 32. Wayne P. 2009. Evaluation of Stability of In Vitro Diagnostic Reagents; Approved
393 Guidelines. Clinical and Laboratory Standards Institute EP25-A.
- 394 33. Defense USDo. 2008. Environmental Engineering Considerations and Laboratory Tests.
395 MIL-STD-810G.
- 396 34. Banoo S, Bell D, Bossuyt P, Herring A, Mabey D, Poole F, Smith PG, Sriram N,
397 Wongsrichanalai C, Linke R, O'Brien R, Perkins M, Cunningham J, Matsoso P,
398 Nathanson CM, Olliaro P, Peeling RW, Ramsay A. 2006. Evaluation of diagnostic tests
399 for infectious diseases: general principles. *Nat Rev Microbiol* 4:S21-31.
- 400 35. Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, Niemeyer D,
401 Jones TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brunink S, Schneider J,
402 Ehmann R, Zwirgmaier K, Drosten C, Wendtner C. 2020. Virological assessment of
403 hospitalized patients with COVID-2019. *Nature* 581:465-469.
- 404 36. Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. SARS-CoV-2, SARS-CoV, and
405 MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a
406 systematic review and meta-analysis. *The Lancet Microbe* doi:10.1016/S2666-
407 5247(20)30172-5.

408

409

410

411

412

413

414

415

416


417

418

419

420

421



430 **Figure 1. COVID-19 case numbers and mean temperatures globally.** A. World map
431 representing global temperature distribution based on maximum temperature of the
432 warmest month (°C) freely available from WorldClim 2 (19). B. Graph represents total
433 COVID-19 cases in the ten most affected countries globally by 25th of November 2020
434 (20).

435


436

437

438

439

440



455 **Figure 2. Experimental setup for validation of SARS-CoV-2 Ag-RDTs.** (i): storage and
456 operation at recommended conditions; (ii): recommended storage and operation at
457 tropical conditions; (iii): storage and operation at tropical conditions.

458
459
460
461
462
463
464

	Abbott			ActivXpress			Bioeasy			Clinitest		
Copies/ml	(i)	(ii)	(iii)	(i)	(ii)	(iii)	(i)	(ii)	(iii)	(i)	(ii)	(iii)
3.1x10 ⁹	[Dark Grey]			[Dark Grey]			[Dark Grey]			[Dark Grey]		
7.0x10 ⁸	[Dark Grey]			[Dark Grey]			[Dark Grey]			[Dark Grey]		
7.0x10 ⁷	[Dark Grey]			[Dark Grey]			[Dark Grey]			[Dark Grey]		
7.2x10 ⁶	[Dark Grey]			[Dark Grey]			[Dark Grey]			[Dark Grey]		
corrected LOD	1.2x10 ⁸	1.2x10 ⁷	1.2x10 ⁷	1.4x10 ⁸	1.4x10 ⁷	1.4x10 ⁷	7.0x10 ⁵	7.0x10 ⁶	7.0x10 ⁶	1.1x10 ⁵	1.1x10 ⁶	1.1x10 ⁶
	Coris			Genedia			Ichroma			JOYSBIO		
Copies/ml	(i)	(ii)	(iii)	(i)	(ii)	(iii)	(i)	(ii)	(iii)	(i)	(ii)	(iii)
3.1x10 ⁹	[Dark Grey]			[Dark Grey]			[Dark Grey]			[Dark Grey]		
7.0x10 ⁸	[Dark Grey]			[Dark Grey]			[Dark Grey]			[Dark Grey]		
7.0x10 ⁷	[Dark Grey]			[Dark Grey]			[Dark Grey]			[Dark Grey]		
7.2x10 ⁶	[Dark Grey]			[Dark Grey]			[Dark Grey]			[Dark Grey]		
corrected LOD	7.9x10 ⁷	7.9x10 ⁷	7.9x10 ⁷	4.6x10 ⁷	4.6x10 ⁷	4.6x10 ⁷	8.2x10 ⁵	8.2x10 ⁵	8.2x10 ⁶	1.4x10 ⁵	1.4x10 ⁶	1.4x10 ⁶
	NowCheck			Roche			Standard Q					
Copies/ml	(i)	(ii)	(iii)	(i)	(ii)	(iii)	(i)	(ii)	(iii)			
3.1x10 ⁹	[Dark Grey]			[Dark Grey]			[Dark Grey]					
7.0x10 ⁸	[Dark Grey]			[Dark Grey]			[Dark Grey]					
7.0x10 ⁷	[Dark Grey]			[Dark Grey]			[Dark Grey]					
7.2x10 ⁶	[Dark Grey]			[Dark Grey]			[Dark Grey]					
corrected LOD	1.0x10 ⁸	1.0x10 ⁷	1.0x10 ⁷	1.0x10 ⁸	1.0x10 ⁷	1.0x10 ⁷	1.0x10 ⁸	1.0x10 ⁷	1.0x10 ⁷			

	2/2 ++		1 ++; 1 +
	2/2 +		1/2 +
	2/2 ?		1/2 ?
	-		(i) rt - rt
			(ii) rt - 37°C
			(iii) 37°C - 37°C

465
 466 **Figure 3. Sensitivity of SARS-CoV-2 Ag-RDTs decreases at elevated temperatures.**
 467 Analytical sensitivity of SARS-CoV-2 rapid antigen tests upon different storage and
 468 operation conditions; (i): rt storage- rt testing, blue; (ii): rt storage - 37°C 10 min pre-
 469 incubation - 37°C testing, yellow; (iii): 37°C storage - 37°C testing, orange. ++ positive; +
 470 weak positive; - negative; ? unclear result. 1/2, 2/2: number of replicates. LOD: limit of
 471 detection. rt: room temperature.

472
 473
 474
 475
 476

477 **Supplementary Table 1. Analytical Sensitivity of SARS-CoV-2 rapid antigen tests at**
 478 **recommended storage and test conditions**

Test	ActivXpress			Genedia			ichroma			JOYSBIO		
Replicate	1	2	3	1	2	3	1	2	3	1	2	3
SARS-CoV-2 (copies/ml)												
3.1x10 ⁹	++	++	++	++	++	++	++	++	++	++	++	++
7.0x10 ⁸	++	++	++	?	?	?	++	++	++	++	++	++
7.0x10 ⁷	++	++	++	-	-	-	++	++	++	+	+	+
7.2x10 ⁶	-	-	-	-	-	-	-	-	-	-	-	-

479 ++ positive; + weak positive; - negative; ? unclear result. LOD: limit of detection.

480